# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2013 Earnings Results

**Report date:** 2013-05-03 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2013

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 7.05%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.78 | N/A | +68.56% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Confident

Management expressed confidence in their financial performance, particularly in EPS. They emphasized their commitment to pipeline development.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on advancing our pipeline.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance, significantly above expectations, contributed to a 7.05% increase in stock price. The positive surprise indicates effective cost management and operational efficiency. However, the lack of revenue data and guidance leaves some uncertainty about future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2013_